RenovoRx Publishes Positive Early-Stage Data On TAMP Therapy For Locally Advanced Pancreatic Cancer
Portfolio Pulse from Benzinga Newsdesk
RenovoRx has published positive early-stage data on its TAMP therapy for locally advanced pancreatic cancer. The therapy, combined with prior chemoradiation, shows a 27-month overall survival rate. An ongoing Phase III trial is evaluating the targeted chemotherapy delivery. The study was published in The Oncologist.
July 31, 2024 | 12:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RenovoRx's TAMP therapy for pancreatic cancer shows promising early-stage data with a 27-month overall survival rate. An ongoing Phase III trial is evaluating the targeted chemotherapy delivery.
The positive early-stage data and the ongoing Phase III trial are likely to boost investor confidence in RenovoRx, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100